Cedelizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCedelizumab
Drug Alias NameOKT-4ARWJ 49004OKT-4 antibodyOrthoclone OKT4Orthoclone OKT4A +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT-cell surface antigen CD4 inhibitorsAnti-CD4Immunosuppressants
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsRejection of organ transplantationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOrtho-Mcneil Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOrtho-Mcneil Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG